Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cleminorexton · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group A - Narcolepsy Type 1 (Dose 1) | EXPERIMENTAL | - |
| Group A - Narcolepsy Type 1 (Dose 2) | EXPERIMENTAL | - |
| Group A - Narcolepsy Type 1 (placebo) | PLACEBO_COMPARATOR | - |
| Group B - Narcolepsy Type 2 (Dose 1) | EXPERIMENTAL | - |
| Group B - Narcolepsy Type 2 (Dose 2) | EXPERIMENTAL | - |
| Group B - Narcolepsy Type 2 (placebo) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| cleminorexton | DRUG | Oral cleminorexton capsule |
| Placebo | DRUG | matching placebo capsule |
Key Inclusion Criteria: * 18-70 years of age * Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m\^2 (inclusive) * Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD...
Cleminorexton is an investigational small molecule being developed for the treatment of narcolepsy Type 1. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being studied in patients with central disorders of hypersomnolence, including narcolepsy Type 1 and Type 2.
Cleminorexton is being developed by Centessa Pharmaceuticals plc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CNTA. The company is conducting clinical trials to evaluate the safety and efficacy of cleminorexton in patients with narcolepsy.
Cleminorexton is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is recruiting participants to study the drug's effects compared with placebo in patients with central disorders of hypersomnolence.
Cleminorexton is being studied in a Phase 2 clinical trial registered as NCT07598708. This randomized, double-blind, placebo-controlled study is investigating the effects of cleminorexton compared with placebo in participants with central disorders of hypersomnolence, including narcolepsy Type 1 and Type 2. The trial is recruiting 222 participants in the United States.
Cleminorexton is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being studied for its effects on symptoms of narcolepsy, a neurological disorder characterized by excessive daytime sleepiness and sudden loss of muscle tone.